These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 28155013)

  • 1. Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).
    Pettijohn EM; Ma S
    Curr Hematol Malig Rep; 2017 Feb; 12(1):20-28. PubMed ID: 28155013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
    Hill RJ; Lou Y; Tan SL
    Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents.
    Maly J; Blachly JS
    Curr Hematol Malig Rep; 2016 Feb; 11(1):52-60. PubMed ID: 26893063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
    McCaig AM; Cosimo E; Leach MT; Michie AM
    Br J Haematol; 2011 Apr; 153(2):199-211. PubMed ID: 21352196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards targeted therapy of chronic lymphocytic leukemia.
    Niemann CU; Jones J; Wiestner A
    Adv Exp Med Biol; 2013; 792():259-91. PubMed ID: 24014301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.
    Abou Zahr A; Bose P; Keating MJ
    Expert Opin Pharmacother; 2017 Jun; 18(9):857-873. PubMed ID: 28446054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
    Varma G; Johnson TP; Advani RH
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):543-54. PubMed ID: 27379948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
    Davids MS; Brown JR
    Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia.
    Lewis RI; Vom Stein AF; Hallek M
    Blood; 2024 Aug; 144(6):601-614. PubMed ID: 38776510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
    Mato A; Jauhari S; Schuster SJ
    Am J Hematol; 2015 Jul; 90(7):657-64. PubMed ID: 25808792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
    Buchner M; Fuchs S; Prinz G; Pfeifer D; Bartholomé K; Burger M; Chevalier N; Vallat L; Timmer J; Gribben JG; Jumaa H; Veelken H; Dierks C; Zirlik K
    Cancer Res; 2009 Jul; 69(13):5424-32. PubMed ID: 19549911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reaserch Advance on Inhibitor Targeting at the B-Cell Receptor Pathway in Chronic Lymphocytic Leukemia --Review].
    Ji TT; Chen QN; Tao SD; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):708-712. PubMed ID: 32319422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research Progress of Targeted Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma --Review].
    Chen D; Wang MY; Tian C
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel treatments for chronic lymphocytic leukemia and moving forward.
    Brown JR; Porter DL; O'Brien SM
    Am Soc Clin Oncol Educ Book; 2014; ():e317-25. PubMed ID: 24857119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL-2 Inhibitors, Present and Future.
    Ryan CE; Davids MS
    Cancer J; 2019; 25(6):401-409. PubMed ID: 31764121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
    Feng G; Wang X
    Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies.
    Lukas M; Velten B; Sellner L; Tomska K; Hüellein J; Walther T; Wagner L; Muley C; Wu B; Oleś M; Dietrich S; Jethwa A; Bohnenberger H; Lu J; Huber W; Zenz T
    Leukemia; 2020 Nov; 34(11):2934-2950. PubMed ID: 32404973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.